Hemorheology

GC Biopharma USA Announces Publication Describing Proprietary Cation Exchange Chromatography (CEX) Removing FXIa from a 10% Intravenous Immunoglobulin (GC5107) Preparation

Retrieved on: 
Tuesday, December 5, 2023
Frontiers in Cardiovascular Medicine, GC, Safety, Plasma, Kidney disease, Immobilization, CEX, Hemorheology, Patient, Biopharma LLC, IVIG, Manuscript, Cardiology, Pharmaceutical industry

TEANECK, N.J., Dec. 5, 2023 /PRNewswire/ -- GC Biopharma USA announced that a manuscript describing its landmark CEX technology, which removes FXIa from its 10% intravenous immunoglobulin (IVIG) preparation (GC5107), was published in Frontiers in Cardiovascular Medicine.

Key Points: 
  • TEANECK, N.J., Dec. 5, 2023 /PRNewswire/ -- GC Biopharma USA announced that a manuscript describing its landmark CEX technology, which removes FXIa from its 10% intravenous immunoglobulin (IVIG) preparation (GC5107), was published in Frontiers in Cardiovascular Medicine.
  • Numerous licensed IG products formulated for intravenous (IV) or subcutaneous administration are available.
  • GC Biopharma USA's rigorous studies have confirmed that a novel 10% IVIG manufacturing process, including CEX chromatography, is a reliable means of removing FXIa from the final preparation.
  • It is hoped that this novel proprietary manufacturing process will further support the product's safety—especially for high-risk patients who require IVIG.

Boundless Hydrogen Water Announces New Sponsorship and Flavors

Retrieved on: 
Tuesday, April 18, 2023
Hydrogen, Kostya Tszyu, Land Down Under, Hemorheology, Boundless, WBO, Somnolence, News, Boxing, Fatigue, Fight Night, Phosphorus, Film industry, Coffee

FORT LAUDERDALE, Fla., April 18, 2023 /PRNewswire/ -- Boundless Hydrogen Water is an Australian beverage company with a sparkling reputation for its innovative hydrogen-infused H2O. The company's products have historically delivered the bodily benefits of hydrogen ingestion in a format that has no calories or sugar. Now, the brand is taking the next step — or rather, a two-part leap — in the form of both sponsoring famed boxer Tim Tszyu and expanding its product selection in an exciting new direction.

Key Points: 
  • FORT LAUDERDALE, Fla., April 18, 2023 /PRNewswire/ -- Boundless Hydrogen Water is an Australian beverage company with a sparkling reputation for its innovative hydrogen-infused H2O.
  • To top it off, thanks to the new sponsorship, the famed boxer will be sporting Boundless hydrogen water the next time he enters the ring to attempt to extend his undefeated career.
  • As if the Fight Night sponsorship wasn't big enough news, Boundless is also in the midst of rapidly expanding its drink selection.
  • Currently, the company is about to roll out its first flavored option in the form of its Acai Hydrogen Water.

Insights on the Vegan Supplements Global Market to 2027 - Shifting Consumer Inclinations Toward a Healthier Lifestyle is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
Vitamins, Supplements, Health, Inflammation, Chocolate, Meat, Industry, Calcium, Iodine, Milk, Protein, Adoption, Dietary fiber, Hemorheology, Intake, COVID-19, Vanilla, Growth, Iron, Zinc, Egg, Nutrient, Capsule, Powder, Risk, Carbon, Tablet, Awareness, Dietary supplement, Potash

Vegan supplements refer to additional nutrients that are derived from plant-based sources to fulfill the nutritional requirements of the human body.

Key Points: 
  • Vegan supplements refer to additional nutrients that are derived from plant-based sources to fulfill the nutritional requirements of the human body.
  • This is further supported by the increasing instances of various lifestyle diseases and the shifting consumer inclination toward a healthier lifestyle.
  • Key Questions Answered in This Report:
    How has the global vegan supplements market performed so far and how will it perform in the coming years?
  • What is the structure of the global vegan supplements market and who are the key players?

Octapharma USA to Present Clinical Overview of Dermatomyositis During The Myositis Association’s Annual Conference

Retrieved on: 
Wednesday, September 7, 2022
Health, Managed Care, Clinical Trials, Research, Pharmaceutical, Science, Kidney failure, Inflammation, Patient, Lists of diseases, National Center for Advancing Translational Sciences, Muscle, Safety, Human services, Kidney, Degenerative disease, Hemorheology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Swelling, Risk factor, Disease, Pulmonary fibrosis, Arthralgia, Estrogen, RN, Death, United States Department of Health and Human Services, Critical care, Food, Skin, Immobilization, Myositis, National Institutes of Health, DM, Multimedia, Symbiosis, Microdeletion syndrome, Plasma, National, Conference, FDA, Sucrose, Immunoglobulin therapy, Adult, Thrombosis, Risk, Immune-mediated inflammatory diseases, Hematology, Octapharma, Polymyositis, TMA, BSN, Pharmaceutical industry, Immunotherapy, Dermatomyositis, Health

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    We are excited to have Octapharma participate in the 2022 International Annual Patient Conference, said TMA Executive Director Chrissy Thornton.
  • Octapharmas pivotal clinical research on DM has been an important resource for the myositis community.
  • Octapharma is committed to developing life-saving and life-enhancing therapies for patients with rare diseases, including dermatomyositis, said Octapharma USA President Flemming Nielsen.
  • Laurel Cherwin, RN, BSN, Octapharma USA Clinical Nurse Educator, will present a 90-minute clinical overview of dermatomyositis during the conference.

WERFEN ANNOUNCES WORLDWIDE COMMERCIAL RELEASE OF GEMWEB® LIVE REAL-TIME ONSCREEN VIEWER

Retrieved on: 
Monday, July 25, 2022
IBM Aptiva, Blood, Chrysler, POC, Company, Clopidogrel, Originality, GEM, Heparin, OEM, Elective surgery, Sigma, Solution, Compliance, ACD, Hemostasis, Patent, Agilent ChemStation, CO-oximeter, Data management, Name, Time, Catheter, ACL, Hospital, Health, Hemorheology, High-dependency unit, Autoloader, Efficiency, Original equipment manufacturer, Accreditation, Medical device, Medical imaging, Werfen, Autoimmunity

BEDFORD, Mass., July 25, 2022 /PRNewswire/ -- Werfen today announced the worldwide commercial release of GEMweb Live, a real-time onscreen viewer of diagnostic test results for cardiac surgical procedures. Comprehensive, rapid test results are viewed in real-time on one screen, designed to help guide goal-directed therapy and other critical needs—before, during and after surgery.

Key Points: 
  • BEDFORD, Mass., July 25, 2022 /PRNewswire/ -- Werfen today announced the worldwide commercial release of GEMweb Live, a real-time onscreen viewer of diagnostic test results for cardiac surgical procedures.
  • A digital solution, GEMweb Live coordinates care, enabling time-critical clinical decisions in the cardiovascular operating room (CVOR) by displaying consolidated results.
  • Now, GEMweb Live delivers real-time results throughout a cardiac procedure in one glance.
  • A multidisciplinary approach to patient management, GEMweb Live supports operational efficiency during time-sensitive procedures such as cardiac surgery.

FDA Approves Octapharma’s cutaquig® 16.5% for Pediatric PI Patients, Providing Flexible Treatment Options

Retrieved on: 
Tuesday, December 7, 2021
Biotechnology, FDA, Hospitals, Health, Pharmaceutical, Physician, Risk, Research, Health, Patient, Thrombosis, Bacterial pneumonia, Lists of diseases, Estrogen, PID, 1978 Chilean national consultation, Immune system, Plasma, Octapharma, Hemorheology, Injection, Food, View, USA, Risk factor, UCLA School of Dentistry, Microdeletion syndrome, Immobilization, Multimedia, PI, Infection, Meningitis, FDA, Immunodeficiency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Critical care, Hematology, Pharmaceutical industry

The FDA previously approved cutaquig for adults with PI.

Key Points: 
  • The FDA previously approved cutaquig for adults with PI.
  • The FDA previously approved cutaquig for adults with PI.
  • The FDA approval also provides more flexible options by permitting more frequent or less frequent infusions, which can be advantageous based on a patients pharmacokinetic and clinical response.
  • The FDA approval of cutaquig is based on the results of two clinical trials, which observed 75 PI patients, 37 adults and 38 pediatric patients between ages 2 and 17.

FDA Orphan Drug Approval: Octapharma’s Octagam® 10% Receives 7 Years of Market Exclusivity for Adult Dermatomyositis

Retrieved on: 
Monday, August 30, 2021
Health, FDA, Other Health, Other Science, Research, Science, Pharmaceutical, Immunoglobulin therapy, Sucrose, Hemorheology, Microdeletion syndrome, Risk factor, USA, National Center for Advancing Translational Sciences, Kidney failure, Human services, Octapharma, Skin, Diagnosis, Muscle, Physician, National Center for Health Research, Research, Immobilization, Food, Death, Marketing, Critical care, Inflammation, Multimedia, DOI, Kidney, DM, Safety, Risk, Mortality, National, Patient, Estrogen, Polymyositis, Plasma, FDA, National Institutes of Health, Rash, Thrombosis, Hematology, United States Department of Health and Human Services, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Degenerative disease, Pharmaceutical industry, Vaccine

We expect that Octagam 10% may become the first treatment option for the vast majority of adults with DM given the outstanding results from the ProDERM clinical trial.

Key Points: 
  • We expect that Octagam 10% may become the first treatment option for the vast majority of adults with DM given the outstanding results from the ProDERM clinical trial.
  • Dermatomyositis is a rare idiopathic autoimmune disorder of unknown cause affecting approximately 10 out of every million U.S. residents.
  • After market approval for the orphan designation, the FDA/OOPD will award seven years of market exclusivity.
  • For patients at risk of thrombosis, renal dysfunction or renal failure, administer Octagam 10% at the minimum infusion rate practicable.

Blood Viscometer Market 2019-2023 | Evolving Opportunities with Anton Paar and Benson Viscometers | Technavio

Retrieved on: 
Wednesday, November 13, 2019
Medical devices, Health, Fluid mechanics, Viscosity, Measuring instruments, Liquids, Physical sciences, Fluid dynamics, Polymers, Viscometer, Hemorheology, Anton Paar

View the full release here: https://www.businesswire.com/news/home/20191113005298/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191113005298/en/
    Technavio has announced its latest market research report titled global blood viscometer market 2019-2023.
  • In addition, the rising growth opportunities in emerging economies are anticipated to further boost the growth of the blood viscometer market.
  • Valuable information regarding the risk of vascular disorders can easily be obtained by blood viscometer which plays a crucial role in assessing blood viscosity.
  • Major Five Blood Viscometer Market Companies:
    Anton Paar offers Rolling-ball viscometer Lovis 2000 M/ME.

Blood Viscometer Market Forecast Report, 2023 - Top Key Players Analyzed: Anton Paar GmbH, Benson Viscometers, BioFluid Technology, RheoSense, & Thermo Fisher Scientific: Radiant Insights, Inc.

Retrieved on: 
Wednesday, June 12, 2019
Fluid mechanics, Measuring instruments, Viscosity, Fluid dynamics, Liquids, Physical sciences, Polymers, Viscometer, Rheology, Hemorheology, Anton Paar, Trend

This test is performed on the basis of blood viscosity rates in the particular organ of the body.

Key Points: 
  • This test is performed on the basis of blood viscosity rates in the particular organ of the body.
  • The leading players in blood viscometers market can be listed as BioFluid Technology, Anton Paar, Thermo Fisher Scientific, Benson Viscometers, China Beijing Steellex Scientific Instrument, and RheoSense.
  • The 'Global Blood Viscometer Market Outlook 2018-2023' offers detailed coverage of blood viscometer industry and presents main market trends.
  • The market research gives historical and forecast market size, demand, end-use details, price trends, and company shares of the leading blood viscometer producers to provide exhaustive coverage of the market for blood viscometer.

Blood Viscometer Market Forecast Report, 2023 - Top Key Players Analyzed: Anton Paar GmbH, Benson Viscometers, BioFluid Technology, RheoSense, & Thermo Fisher Scientific: Radiant Insights, Inc.

Retrieved on: 
Wednesday, June 12, 2019
Fluid mechanics, Measuring instruments, Viscosity, Fluid dynamics, Liquids, Physical sciences, Polymers, Viscometer, Rheology, Hemorheology, Anton Paar, Trend

This test is performed on the basis of blood viscosity rates in the particular organ of the body.

Key Points: 
  • This test is performed on the basis of blood viscosity rates in the particular organ of the body.
  • The leading players in blood viscometers market can be listed as BioFluid Technology, Anton Paar, Thermo Fisher Scientific, Benson Viscometers, China Beijing Steellex Scientific Instrument, and RheoSense.
  • The 'Global Blood Viscometer Market Outlook 2018-2023' offers detailed coverage of blood viscometer industry and presents main market trends.
  • The market research gives historical and forecast market size, demand, end-use details, price trends, and company shares of the leading blood viscometer producers to provide exhaustive coverage of the market for blood viscometer.